- Home
- UROY vs CLLS Comparison
UROY vs CLLS Comparison
Compare UROY & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UROY | CLLS |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | Canada | France |
| Employees | 14 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.6M | 394.4M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | UROY | CLLS |
|---|---|---|
| Price | $3.03 | $2.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | ★ 2.2M | 25.6K |
| Earning Date | 03-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $279.20 | N/A |
| Revenue Next Year | N/A | $0.98 |
| P/E Ratio | $1,584.46 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.42 | $2.00 |
| 52 Week High | $5.52 | $5.48 |
Technical Indicators
Market Signals| Indicator | UROY | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 45.30 |
| Support Level | $2.67 | $2.70 |
| Resistance Level | $4.01 | $3.40 |
| Average True Range (ATR) | 0.15 | 0.13 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 89.32 | 32.50 |
Price Performance
Historical ComparisonAbout UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.